Brookdale Senior Living (BKD) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
Ortelius Advisors, owning 1.3% of shares, is seeking to elect six new directors to address years of underperformance and chronic undervaluation.
The campaign follows the board’s delayed CEO transition and recent defensive board refreshes, which Ortelius views as insufficient.
Ortelius argues for a stockholder-driven overhaul, citing poor operational metrics, declining margins, and significant destruction of stockholder value over the past seven years.
The proxy contest aims to install directors with deep industry, financial, and turnaround expertise to unlock long-term value.
Voting matters and shareholder proposals
Stockholders are asked to elect up to eight directors, including six Ortelius nominees and two unopposed company nominees, using a universal proxy card.
Proposals include an advisory vote on executive compensation and ratification of Ernst & Young LLP as the independent auditor for 2025.
Ortelius recommends voting for its nominees, against the executive compensation proposal, and for the auditor ratification.
Voting instructions emphasize using the WHITE universal proxy card and detail procedures for record and beneficial owners.
Board of directors and corporate governance
The board will be reduced to eight members at the annual meeting, with plans to expand to nine upon hiring a new CEO.
Ortelius’ six nominees bring expertise in senior housing, REITs, financial management, operational turnarounds, and corporate governance.
If five Ortelius nominees are elected, they will form a board majority and seek to collaborate with remaining directors to enhance value.
Ortelius nominees have no material relationships or transactions with the company and are considered independent under NYSE standards, subject to board determination.
Latest events from Brookdale Senior Living
- Operational focus, targeted CapEx, and market-driven M&A support growth amid strong demand.BKD
Barclays 28th Annual Global Healthcare Conference10 Mar 2026 - Record 2025 EBITDA and occupancy set stage for robust 2026 growth and portfolio streamlining.BKD
Q4 202519 Feb 2026 - Q2 saw 20% Adjusted EBITDA growth, higher occupancy, but a wider net loss on higher costs.BKD
Q2 20241 Feb 2026 - 2026 targets $502–$516M Adjusted EBITDA and 8–9% RevPAR growth, led by operational transformation.BKD
Investor Day 202630 Jan 2026 - Q3 2024 delivered 15% EBITDA growth, higher occupancy, and $610M in acquisitions pending.BKD
Q3 202415 Jan 2026 - Strategic acquisitions, strong occupancy, and HealthPlus expansion drive positive 2025 outlook.BKD
Stephens 26th Annual Investment Conference | NASH202413 Jan 2026 - Accelerating occupancy, strong cash flow, and innovation position for sustained growth.BKD
Barclays 27th Annual Global Healthcare Conference26 Dec 2025 - 2024 results beat guidance; 2025 targets 11%-15% EBITDA growth and positive cash flow.BKD
Q4 202415 Dec 2025 - Contested director election, performance-based pay, and auditor ratification headline the 2025 proxy.BKD
Proxy Filing1 Dec 2025